Results 101 to 110 of about 628,495 (277)

The Effects of a Submaximal Endurance Swimming Training Period and Cadmium Poisoning during Pregnancy on the Hepatocyte Growth Factor Response in Neonatal Rats

Majallah-i Dānishgāh-i ̒Ulūm-i Pizishkī-i Qum, 2015
Background and Objectives: Exposure to cadmium in early pregnancy has long-term effects on the growth and function of the liver. One of the pathways that controls proliferation of the fetal liver involves hepatocyte growth factor (HGF).
Hossein Ali Asgharzade Oliaei, Shadmehr Mirdar Harijani, Narges Mousavi   +2 more
doaj  

FBXO44 Regulates FOXP1 Degradation Through AURKA‐Dependent Phosphorylation to Promote Colorectal Cancer Progression

Advanced Science
Emerging evidence highlights the role of SCF E3 ligases, consisting of SKP1, cullin‐1, and F‐box proteins, in cancer biology by regulating the ubiquitination and degradation of key proteins.
Hongxu Nie, Hengjie Xu, Sheng Yang, Chuanxin Tian, Tuo Wang, Chi Jin, Zhihao Chen, Xiaowei Wang, Junwei Tang, Yifei Feng, Yueming Sun   +10 more
doaj   +1 more source

Tumor mutational burden as a determinant of metastatic dissemination patterns

Molecular Oncology, EarlyView.
This study performed a comprehensive analysis of genomic data to elucidate whether metastasis in certain organs share genetic characteristics regardless of cancer type. No robust mutational patterns were identified across different metastatic locations and cancer types.
Eduardo Candeal, Andrea Moreno‐Manuel, Miguel Salvadó‐Pertierra, Cristina Santos‐Vivas, Rebeca Sanz‐Pamplona   +4 more
wiley   +1 more source

The degradation of p53 and its major E3 ligase Mdm2 is differentially dependent on the proteasomal ubiquitin receptor S5a. [PDF]

, 2013
p53 and its major E3 ligase Mdm2 are both ubiquitinated and targeted to the proteasome for degradation. Despite the importance of this in regulating the p53 pathway, little is known about the mechanisms of proteasomal recognition of ubiquitinated p53 and
A Arlt, A Haririnia, A Hishiya, A Peth, A Sparks, AK Hock, AM Ruschak, AS Fatimababy, B Cross, C Brignone, C Wojcik, CF Cheok, D Finley, D Pei, EG Mimnaugh, G Lozano, GL Bond, H Fu, H Fu, H Higashitsuji, H Hiyama, H Inuzuka, H Inuzuka, H Kawahara, HT Kim, I Dikic, J Boehringer, J Das, J Hamazaki, JD Oliner, JD Shaughnessy Jr., JM Stommel, JM Winget, K Husnjak, K Itahana, L Bedford, LF Stevenson, LJ Crawford, LK Linares, LR Dick, LT Vassilev, M Elangovan, M Elangovan, M Isasa, M K Saville, M Kaur, M Wade, M Wade, MD Kaeser, MF Kleijnen, MH Glickman, MJ Lee, MK Saville, MP Bousquet-Dubouch, N Allende-Vega, N Allende-Vega, N Allende-Vega, N Gallastegui, NP Dantuma, NP Dantuma, P Robertson, P Sdek, P Young, PG Santamaria, Q Xu, Q Zhu, R Kulikov, R Verma, S Carter, S Dayal, S Dayal, S Elsasser, S Glockzin, S Menendez, S Nickell, S Raasi, SJ Wei, T Kaneko, T Mayor, T Szlanka, TA Gomez, V Su, VD Nair, XM Sun, Y Jin, Y Kravtsova-Ivantsiv, Y Midorikawa, Y Saeki, Y Wan, YA Lam, YH Shen, YV Wang, Z Lipinszki, Z Lipinszki   +93 more
core   +3 more sources

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

Correlation of the differential expression of PIK3R1 and its spliced variant, p55α, in pan‐cancer

Molecular Oncology, EarlyView.
PIK3R1 undergoes alternative splicing to generate the isoforms, p85α and p55α. By combining large patient datasets with laboratory experiments, we show that PIK3R1 spliced variants shape cancer behavior. While tumors lose the protective p85α isoform, p55α is overexpressed, changes linked to poorer survival and more pronounced in African American ...
Ishita Gupta, Yang Song, Madeleine Ndahayo, Anirudh Saxena, Theresa Guo, Dylan Z. Kelley, Jessica Gore, Andrew Hennigan, Alexa Anderson, John C. Papadimitriou, Daria A. Gaykalova   +10 more
wiley   +1 more source

Tumour–host interactions in Drosophila: mechanisms in the tumour micro‐ and macroenvironment

Molecular Oncology, EarlyView.
This review examines how tumour–host crosstalk takes place at multiple levels of biological organisation, from local cell competition and immune crosstalk to organism‐wide metabolic and physiological collapse. Here, we integrate findings from Drosophila melanogaster studies that reveal conserved mechanisms through which tumours hijack host systems to ...
José Teles‐Reis, Tor Erik Rusten
wiley   +1 more source

Tumor Heterogeneity at Protein Level as an Independent Prognostic Factor in Endometrial Cancer

Translational Oncology, 2014
Intratumor heterogeneity implies heterogeneous protein function, facilitating tumor adaptation which results in therapeutic failure. We hypothesized that tumor heterogeneity at protein level may influence the course of the disease.
Anna Supernat, Sylwia Łapińska-Szumczyk, Hanna Majewska, Jacek Gulczyński, Wojciech Biernat, Dariusz Wydra, Anna J. Żaczek   +6 more
doaj   +1 more source

Genetic attenuation of ALDH1A1 increases metastatic potential and aggressiveness in colorectal cancer

Molecular Oncology, EarlyView.
Aldehyde dehydrogenase 1A1 (ALDH1A1) is a cancer stem cell marker in several malignancies. We established a novel epithelial cell line from rectal adenocarcinoma with unique overexpression of this enzyme. Genetic attenuation of ALDH1A1 led to increased invasive capacity and metastatic potential, the inhibition of proliferation activity, and ultimately ...
Martina Poturnajova, Zuzana Kozovska, Ondrej Pos, Kristina Pavlov, Sachin Gulati, Peter Makovicky, Kristina Jakic, Monika Burikova, Eva Sedlackova, Barbora Svitkova, Silvia Tyciakova, Vojtech Bystry, Nicolas Blavet, Boris Tichy, Matej Hrnciar, Jaroslav Budis, Miroslav Tomas, Peter Dubovan, Georgina Kolnikova, Veronika Repaska, Nikoleta Mojzesova, Eva Zomborska, Daniel Pindak, Michal Mego, Tomas Szemes, Miroslava Matuskova   +25 more
wiley   +1 more source

Immune check point inhibitors in BRAF mutated metastatic colorectal cancer: A review

International Journal of Gastrointestinal Intervention
Metastatic colorectal cancers with BRAF mutation are a class of tumors that have a poor prognosis compared to wild type patients. Even if this group has found some hope in targeted therapy with multi-targeted blockade of the mitogen-activated protein ...
Alfredo Colombo, Stefano Cordio, Concetta Maria Porretto   +2 more
doaj   +1 more source